Clinical Implications of Expression of EphA2 and PRMT1 in Non-Small Cell Lung Cancer Patients
Clinical Implications of Expression of EphA2 and PRMT1 in Non-Small Cell Lung Cancer Patients
Sheng Zhang, Rui Qiu, Zhiping Lv, Liying Yang and Wei He*
ABSTRACT
This study aims to investigate the relationship between EphA2 level and PRMT1 expression in non-small cell lung cancer patients (NSCLCP). This a retrospective observational study totally includes 40 participants, and these participants are divided into following two groups: control group (health participants), experimental group (NSCLCP), and then all these participants receive standardized bronchoalveolar lavage. Participants’ general data are collected and analyzed. EphA2 expression and PRMT1 expression in blood samples are determined by ELISA, and EphA2 protein and PRMT1 protein in bronchoalveolar lavage fluid (BALF) samples are determined by western blotting, and then EphA2 mRNA and PRMT1 mRNA in BALF samples are determined by RT-PCR. The EphA2 expression and PRMT1 expression in experimental group were found clearly higher than those in the control. It appears up-regulation of EphA2 and PRMT1 expression can promote the development of NSCLC.
To share on other social networks, click on any share button. What are these?
